Amira Pharmaceuticals, Inc.
9535 Waples Street
Suite 100
San Diego
California
92121
United States
Tel: 858-228-4650
Fax: 858-558-8445
Website: http://www.amirapharm.com/
Email: info@amirapharm.com
About Amira Pharmaceuticals, Inc.
Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a privately held small molecule pharmaceutical company focused on the discovery and early development of compounds to treat inflammatory disease. The company combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.
35 articles about Amira Pharmaceuticals, Inc.
-
Panmira Pharmaceuticals, LLC. and FLAP LLC Spun Out of Amira Pharmaceuticals, Inc.
9/9/2011
-
Bristol-Myers Squibb Company Completes Acquisition of Amira Pharmaceuticals, Inc.
9/8/2011
-
Bristol-Myers Squibb Company to Pay Up to $475 Million for Amira Pharmaceuticals, Inc., Scoops Up Lung Drug
7/22/2011
-
Amira Pharmaceuticals, Inc. Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
5/2/2011
-
Amira Pharmaceuticals, Inc. Receives Orphan Drug Status for a Novel LPA1 Antagonist, AM152, for the Treatment of Idiopathic Pulmonary Fibrosis
4/19/2011
-
Findings Published in Journal of Pharmacology and Experimental Therapeutics Demonstrate Potential for Amira Pharmaceuticals, Inc.'s LPA1 Receptor Antagonist as an Anti-Fibrotic Agent
1/5/2011
-
Amira Pharmaceuticals, Inc. Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
12/15/2010
-
Amira Pharmaceuticals, Inc. to Present Preclinical, Clinical Data from DP2 Receptor Antagonist Program at Pacifichem 2010
12/14/2010
-
Amira Pharmaceuticals, Inc. Cuts Half of Staff, Scientific Founders Exit as Company Seeks to Conserve Cash
11/29/2010
-
Amira Pharmaceuticals, Inc. Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
10/28/2010
-
Amira Pharmaceuticals, Inc. Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
9/28/2010
-
Amira Pharmaceuticals, Inc. Hits Two Development Milestones Related to FLAP Inhibitor Program
7/19/2010
-
Amira Pharmaceuticals, Inc. Announces AM103 and AM803 Patent Grant in the United Kingdom
7/14/2010
-
Amira Pharmaceuticals, Inc. Announces Second DP2 Antagonist Patent Grant in the United Kingdom
5/26/2010
-
Anti-Fibrotic Data from Amira Pharmaceuticals, Inc.'s LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
5/6/2010
-
Amira Pharmaceuticals, Inc. Announces Patent Grant in United Kingdom
4/22/2010
-
Amira Pharmaceuticals, Inc. Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
2/10/2010
-
Amira Pharmaceuticals, Inc. Achieves Development Milestone Related to FLAP Inhibitor Program
1/7/2010
-
Amira Pharmaceuticals, Inc. Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amira's Lead DP2 Antagonist, AM211 Results Demonstrate Positive Proof of Mechanism
12/3/2009
-
Amira Pharmaceuticals, Inc. to Present at Montgomery Healthcare Conference
10/6/2009